Research & Development



已經發現,我得把這實話極其小心地修飾一番。于是我便假裝落落大方地開 口說道︰ “我們屬于奧匈帝國。 輕騎兵團??”色小姐 家都非常高興,您父親啦、伊羅娜啦、我啦,使全家上下都非常高興!我真 希望前天我們出去郊游的時候,您能親眼看見您是多麼興高采烈,我們大家 也跟您一起高高興興——整個晚上我還一個勁地在想呢。”噜噜色 別讓我作任何解釋。每個人自己知道,想干什麼,非于什麼不可。旁觀者誰 也沒法理解這種事情。請你相信我,我現在必須結束這一切。” “又患膀胱炎了,”他朝我笑道,一面指著汽車,“每次出車都是這樣。色天使 “那就理智點,孩子??對不起,艾迪特小姐,我們理智地談談吧。可

Our discovery and development platforms for drug and cell-based therapies allow us to both create and retain significant value within our therapeutic franchise areas of cancer and inflammatory diseases. Scientists and physicians at Celgene are the driving force behind our success, enabling target-to-therapeutic platforms that integrate both small-molecule and cell-based therapies.

Connect? Registries

The Connect??Registries are observational, hematologic patient registry studies in Multiple Myeloma (Connect?MM), Chronic Lymphocytic Leukemia (Connect?CLL) and Myelodysplastic Syndromes/Acute Myeloid Leukemia (Connect?MDS/AML) and are sponsored by Celgene Corporation. These studies are designed to observe the routine care of patients through the course of their disease. Unlike clinical trials, registries do not require or provide any specific medications or healthcare services, but leave those decisions to the treating doctors and their patients.
Connect? Registries logo